PBF-1650

N/A

Report date: 2024/02/05 16:46:38
NME

Base Information

Drug NamePBF-1650
Drug Alias NamePBF-1650
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAdenosine A1 receptor antagonistsAdenosine A3 receptor antagonists
TargetsAdenosine A3 receptorAdenosine A1 receptor
Therapy Area/IndicationsPsoriasisDermatitis, AtopicMetabolic Dysfunction-Associated Steatotic Liver Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySpain
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPalobiofarma Sl
China Registration ClassN/A

Develop Information

Active CompaniesPalobiofarma Sl
Inactive CompaniesN/A
Active IndicationsDermatitis, AtopicMetabolic Dysfunction-Associated Steatotic Liver Disease
Inactive IndicationsPsoriasis

Other Information

ATC CodeN/A
Related LinksN/A